Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219199 · ClinicalTrials.gov registry record · NA
Residual IDH1-Mutant Tumor Cell Quantification Study
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 105
- Enrollment target
NCT07219199 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 105 participants.
The verdict
NCT07219199, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.
Interventions
- DEVICE UR-ddPCR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-12 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219199
The ClinicalTrials.gov registry entry for NCT07219199 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UR-ddPCR is the first listed.
NCT07219199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07219199 about?
NCT07219199 is a clinical study titled "Residual IDH1-Mutant Tumor Cell Quantification Study". This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.
What is the current status of trial NCT07219199?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 105 participants. The study started on 2025-12. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07219199?
The interventions under investigation include: UR-ddPCR (DEVICE).
Who is sponsoring clinical trial NCT07219199?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.